In case the originator of the data has already been granted marketing approval abroad, a country may decide to base domestic marketing approval on the recognition of the foreign approval. Alternatively, a country may also decide to require the data originator to carry out additional clinical trials, in case it considers the trials undertaken for the foreign approval as insufficient. Instead, it will at least require the generic producer to submit evidence of bioequivalence between the generic drug and the originator’s product, i.e. to show that the copied product performs in the same manner as the originator’s product (the safety and efficacy of which has already been proven).551 By doing so, the generic producer does not make use of the originator’s data, which remains undisclosed and unknown to him, in line with the TRIPS Agreement (see below for details).